drugset / Trial / NCT00154245

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

NCT00154245

Phase 4 Completed 20 enrolled Novartis
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The study is a one-year prospective, open-label, safety and efficacy study. De novo renal transplant recipients will be receiving cyclosporine, 1.44g EC-MPS (720 mg b.i.d.), and corticosteroids .The study will consist of a 12-month open-label treatment period on EC-MPS.

Timeline

Start
2004-01
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown 720 mg

Indications

No indication recorded.